Summary:
The objective of this study is to assess the safety and efficacy of 3 different doses of CTP-692 administered once daily for 12 weeks to adult patients with schizophrenia on stable dopaminergic antipsychotic medication.
Inclusion Criteria:
- Physician confirmed DSM-V diagnosis of schizophrenia for the past 2 years
- Patients with clinically stable schizophrenia with residual symptoms defined as PANSS total score of 70-110
- Patients currently treated with one antipsychotic medication
Qualified Participants May Receive:
Monetary compensation and study-related care at no cost to the participant